Form PTO-1449 (modified)	Atty. Docket No.: CHEP:015US	Serial No.: 10/561,034
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	Applicant: Laurence CHRISTA *et al.*	
(Use several sheets if necessary)	Filing Date: July 24, 2006	Group: 1646

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Pages 1-2*

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C4	"Comparison of short versus full length ALF-5755 activity on primary culture of rat hepatocytes," *INSERM*, Research Report of Dr. Didier Samuel, M.D., Ph.D., pages 1-7.
	C5	"Evaluation Report, Research Unit: Physiopathogenesis and treatment of fulminant hepatitis and liver cancer," *French Research and Education Evaluation Agency (AERES)*, 11 pages, December 2008.
	C6	"Guidance for industry – For the submission of chemistry, manufacturing, and controls information for a therapeutic recombinant DNA-derived product or a monoclonal antibody product for *in vivo* use," *Center for Biologics Evaluation and Research (CBER) and Center for Drug Evaluation and Research (CDER)*, August 1996.
	C7	"Guidance for industry – Q6B specifications: test procedures and acceptance criteria for biotechnological/biological products," *U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), and Center for Biologics Evaluation and Research (CBER)*, pages 1-21, August 1999.
	C8	"Guideline for industry – Quality of biotechnological products: stability testing of biotechnological/biological products," *Expert Working Group (Quality) of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)*, pages 1-10, July 1996.
	C9	"Points to consider in the production and testing of new drugs and biologicals produced by recombinant DNA technology," *Office of Biologics Research and Review – Center for Drugs and Biologics*, Draft, April 10, 1985.

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No.: CHEP:015US	Serial No.: 10/561,034
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	Applicant: Laurence CHRISTA *et al.*	
(Use several sheets if necessary)	Filing Date: July 24, 2006	Group: 1646

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Pages 1-2*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C10	"Production and quality control of medicinal products derived by recombinant DNA technology," *European Agency for the Evaluation of Medicinal Products (EMEA)*, pages 205-216, December 1994.
	C11	"Quality of biotechnological products: stability testing of biotechnological/biological products," *European Agency for the Evaluation of Medicinal Products (EMEA)*, pages 263-273, December 1995.
	C12	"Use of transgenic animals in the manufacture of biological medicinal products for human use," *European Agency for the Evaluation of Medicinal Products (EMEA)*, pages 287-294, December 1994.
	C13	Christa *et al.*, "High expression of the human hepatocarcinoma-intestine-pancreas/pancreatic-associated protein (HIP/PAP) gene in the mammary gland of lactating transgenic mice – Secretion into the milk and purification of the HIP/PAP lectin," *Eur. J. Biochem.*, 267:1665-1671, 2000.

60285642.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.